The American Academy of Otolaryngic Allergy (AAOA) encourages the preferential practice of administering immunotherapy in a medical office setting with professionals trained in the recognition and management of anaphylactic reactions. The AAOA also recognizes the need for patients to make decisions affecting their personal healthcare choices, including the choice of home-administered immunotherapy, after receiving risk and benefit information from qualified healthcare providers through an informed consent process. The physician should assess the risks and benefits of in-office versus home-administered immunotherapy for each individual patient, taking into account the severity of allergic disease, coexisting medical conditions and medications, and other relevant individual patient characteristics. The risk and benefits should be discussed with each individual patient.

- The AAOA recognizes that subcutaneous immunotherapy is a valuable treatment option for patients suffering from allergic diseases, such as allergic rhinitis and conjunctivitis.

- The AAOA also recognizes the safest place for administration of injection immunotherapy is in the office of a medical professional trained in the administration of immunotherapy and the recognition and treatment of potential immunotherapy complications, including anaphylaxis. The relative safety of home-administered immunotherapy when patients are properly selected based on physician risk assessment has been documented.\(^1\)

- Some patients, due to life factors that limit their ability to follow a regime of immunotherapy injections restricted to a medical office environment, may have access issues to allergy care. Limited access to immunotherapy could increase a patient’s risk of developing a more morbid allergic disease such as allergic asthma.

- Medical professionals regularly assess the risks and benefits of a particular medical intervention, explain these risks and benefits to a patient, and allow the patient to make decisions on which medical treatments to accept (in an informed consent process). The informed consent process is commonly practiced without formal documentation (such as with common medications), but sometimes is formalized in a signed document, particularly with interventions considered to carry more significant risk of adverse effects (such as surgical interventions and some medications with more significant risks of adverse effects).

- Patients are routinely given medical treatment options with recognized risks to accomplish desired potential benefits. The AAOA affirms the right of patients to make decisions about personal medical therapy options when they are properly informed of the potential risks and benefits by a qualified medical professional.

- If a medical professional determines a particular patient has an acceptable risk/benefit ratio to allow the option of home immunotherapy, and the patient decides to proceed with the option of home immunotherapy, the physician should provide clear directions and training on the proper technique for handling and administering the immunotherapy products. The patient should also be trained in the recognition and treatment of potential adverse events, including the availability and use of epinephrine auto-injectors. All injections at home should be given in the presence of another responsible adult provided with instructions in the recognition of potential anaphylaxis and basic initial treatment of anaphylaxis, including epinephrine auto-injector administration and contacting emergency services.